Search details
1.
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 24(6): 646-657, 2023 06.
Article
in English
| MEDLINE | ID: mdl-37182538
2.
Real-world treatment patterns and outcomes of pyrotinib-based therapy in patients with HER2-positive advanced breast cancer (PRETTY): A nationwide, prospective, observational study.
Int J Cancer
; 153(10): 1809-1818, 2023 11 15.
Article
in English
| MEDLINE | ID: mdl-37543965
3.
A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments.
Int J Cancer
; 152(10): 2134-2144, 2023 05 15.
Article
in English
| MEDLINE | ID: mdl-36621000
4.
The mixed subtype has a worse prognosis than other histological subtypes: a retrospective analysis of 217 patients with metaplastic breast cancer.
Breast Cancer Res Treat
; 200(1): 23-36, 2023 Jul.
Article
in English
| MEDLINE | ID: mdl-37160814
5.
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study.
Breast Cancer Res Treat
; 197(3): 489-501, 2023 Feb.
Article
in English
| MEDLINE | ID: mdl-36459284
6.
Epidemiology and Aetiology of Tinea Capitis in Wuhan and Its Surrounding Areas from 2011 Till the Present: A Single-Center Retrospective Study.
Mycopathologia
; 188(5): 479-488, 2023 Oct.
Article
in English
| MEDLINE | ID: mdl-37185790
7.
A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer.
BMC Med
; 20(1): 321, 2022 10 03.
Article
in English
| MEDLINE | ID: mdl-36184642
8.
Ado-trastuzumab emtansine in the treatment of lung adenocarcinoma with ERBB2 mutation: a case report and literature review.
Anticancer Drugs
; 33(8): 773-777, 2022 09 01.
Article
in English
| MEDLINE | ID: mdl-35946510
9.
Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway.
Mol Ther
; 29(4): 1541-1556, 2021 04 07.
Article
in English
| MEDLINE | ID: mdl-33412308
10.
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.
Lancet Oncol
; 22(3): 351-360, 2021 03.
Article
in English
| MEDLINE | ID: mdl-33581774
11.
Profile and outcome of receptor conversion in breast cancer metastases: a nation-wide multicenter epidemiological study.
Int J Cancer
; 148(3): 692-701, 2021 02 01.
Article
in English
| MEDLINE | ID: mdl-32700765
12.
Multicenter phase II study of apatinib single or combination therapy in HER2-negative breast cancer involving chest wall metastasis.
Chin J Cancer Res
; 33(2): 243-255, 2021 Apr 30.
Article
in English
| MEDLINE | ID: mdl-34158743
13.
Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018).
Cancer
; 126 Suppl 16: 3867-3882, 2020 08 15.
Article
in English
| MEDLINE | ID: mdl-32710660
14.
Single-cell sequencing deciphers a convergent evolution of copy number alterations from primary to circulating tumor cells.
Genome Res
; 27(8): 1312-1322, 2017 08.
Article
in English
| MEDLINE | ID: mdl-28487279
15.
Aetiology of superficial fungal infections of the foot in urban outpatients in mainland China: A multicentre, prospective case study.
Mycoses
; 63(11): 1235-1243, 2020 Nov.
Article
in English
| MEDLINE | ID: mdl-33090565
16.
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(6): 806-815, 2019 06.
Article
in English
| MEDLINE | ID: mdl-31036468
17.
ACT001 can prevent and reverse tamoxifen resistance in human breast cancer cell lines by inhibiting NF-κB activation.
J Cell Biochem
; 120(2): 1386-1397, 2019 Feb.
Article
in English
| MEDLINE | ID: mdl-30450651
18.
Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial.
Lancet Oncol
; 18(3): 371-383, 2017 03.
Article
in English
| MEDLINE | ID: mdl-28209298
19.
Downregulation of delta-aminolevulinate dehydratase is associated with poor prognosis in patients with breast cancer.
Cancer Sci
; 108(4): 604-611, 2017 Apr.
Article
in English
| MEDLINE | ID: mdl-28403546
20.
Decreasing Eukaryotic Initiation Factor 3C (EIF3C) Suppresses Proliferation and Stimulates Apoptosis in Breast Cancer Cell Lines Through Mammalian Target of Rapamycin (mTOR) Pathway.
Med Sci Monit
; 23: 4182-4191, 2017 Aug 30.
Article
in English
| MEDLINE | ID: mdl-28854163